The Biostatistics/Data Management Center - M.D. Anderson Cancer Center (MDACC) will provide the Primary Data Management and Biostatistical support for Projects 3, 4, and 6, and support the Data Management and Statistical Activities of the RTOG Center for Project 1 and 2. For Project 1 (Chemoprevention Study), the MDACC Center will be the contact office for registration and randomization of CCOP and MDACC patients; receive, edit, and transmit data forms from CCOPs and MDACC to the RTOG office; perform toxicity monitoring for CCOP and MDACC; directly receive, log-in, and transmit all pathology, laboratory specimens, and radiologic meterials. The MDACC Core will receive and track all specimens for Project 2 (Risk Model Study). The core will periodically survey and enter data for Projects 4 (Field Cancerization) and 6 (Role of NRARs in Retinoid Response). For Project 3 (Leukoplakia Study), the core will register and randomize patients; collect and monitor data; perform quality assurance activities; monitor toxicity; and track biologic specimens. The Biostatistics Unit of the core will provide primary statistical analysis for Project 3, 4, and 6 and collaborate with the RTOG Biostatistical Unit for Projects 1 and 2. The establishment of the MDACC Center, closely linked to the RTOG Center, will enable the program to utilize existing, well-established Data Management linkages with the CCOPs, and maintain on-site Data Management and Biostatistical support for projects being performed at MDACC. The Data-Management Office of the Section of Community Oncology and the Biostatistics Resource Group at MDACC have on-going experience with multi-disciplinary, multi-institutional trials and thus are able to utilize firmly established facilities and resources in accomplishing these tasks. The close relationship developed over the last two years with the RTOG Biostatistics/Data Management Center will ensure the smooth integration of the activities of these two components.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA052051-10S1
Application #
6577742
Study Section
Project Start
2002-03-26
Project End
2002-11-30
Budget Start
Budget End
Support Year
10
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Hildebrandt, Michelle A T; Lippman, Scott M; Etzel, Carol J et al. (2012) Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res 18:3705-13
Lee, J Jack; Wu, Xifeng; Hildebrandt, Michelle A T et al. (2011) Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) 4:185-93
Wang, Jianming; Lippman, Scott M; Lee, J Jack et al. (2010) Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. Carcinogenesis 31:1755-61
Zhang, Xiaofan; Yang, Hushan; Lee, J Jack et al. (2010) MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. Carcinogenesis 31:2118-23
Wu, Xifeng; Spitz, Margaret R; Lee, J Jack et al. (2009) Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila) 2:617-24
William Jr, William N; Lee, J Jack; Lippman, Scott M et al. (2009) High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila) 2:22-6
Papadimitrakopoulou, Vassiliki A; Lee, J Jack; William Jr, William N et al. (2009) Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol 27:599-604
Kawaguchi, Hidetoshi; El-Naggar, Adel K; Papadimitrakopoulou, Vali et al. (2008) Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 26:354-60
Wu, Xifeng; Gu, Jian; Dong, Qiong et al. (2006) Joint effect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer. Clin Cancer Res 12:7194-201
Lippman, Scott M; Lee, J Jack (2006) Reducing the ""risk"" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res 66:2893-903

Showing the most recent 10 out of 91 publications